Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04836-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Martina Catalano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, 50139, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Firenze.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
CDK4/6 inhibitors have transformed treatment for HR + HER2 − advanced breast cancer (aBC). However, adverse events (AEs) often lead to dose adjustments or discontinuation, potentially impacting outcomes. This study assessed AE incidence and its effect on survival in patients receiving abemaciclib (AB), ribociclib (RB), or palbociclib (PB).
Methods
A retrospective study of 162 h + HER2 − aBC patients treated with CDK4/6 inhibitors as first-line therapy (July 2017–September 2024) was conducted. AE incidence, progression-free survival (PFS), and overall survival (OS) were analyzed.
Results
Most patients (91.4%) were postmenopausal, with a median follow-up of 24.6 months. AEs occurred in 87% of patients, with grade 3–4 neutropenia most common in PB (79.3%) and RB (80%), while AB caused more diarrhea (66.7%). Dose reductions due to AEs were linked to significantly longer PFS (38.5 vs. 16.3 months, p < 0.001) and OS (NR vs. 32.4 months, p = 0.024). Treatment discontinuation was highest for PB (19.6%), followed by RB (16.9%) and AB (14.9%).
Conclusions
CDK4/6 inhibitors have distinct toxicity profiles. Effective AE management and dose adjustments are crucial for maintaining efficacy, emphasizing the need for AE prediction models to optimize CDK4/6i use in HR + HER2 − aBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, 50139, Italy.
- School of Medicine and Surgery, University of Florence, Florence, 50134, Italy.
- Clinical Oncology, Careggi University Hospital, Florence, Italy.
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
- Unit of Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, 53100, Italy.
- Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Förderung
- Università degli Studi di Firenze
Zitieren
APA
Catalano, M., Cekrezi, G., De Gennaro Aquino, I., Ravizza, D., Paulet, A., Shtembari, K., De Angelis, C., Petrioli, R., Generali, D., & Roviello, G. (2025). Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04836-y
Vancouver
Catalano M, Cekrezi G, De Gennaro Aquino I, Ravizza D, Paulet A, Shtembari K, et al. Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04836-y
BibTeX
@article{Catalano2025,
author = {Catalano, Martina and Cekrezi, Gestiana and De Gennaro Aquino, Irene and Ravizza, Delia and Paulet, Alexandra and Shtembari, Kristian and De Angelis, Claudia and Petrioli, Roberto and Generali, Daniele and Roviello, Giandomenico},
title = {Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04836-y}
}
EUVIMED